Article Link: FDA Approves Semglee (insulin glargine injection) for Type 1 and Type 2 Diabetes HERTFORDSHIRE, England and PITTSBURGH and ...
FDA Approves Nyvepria (pegfilgrastim-apgf), a Biosimilar to Neulasta
Article Link: FDA Approves Nyvepria (pegfilgrastim-apgf), a Biosimilar to Neulasta NEW YORK–(BUSINESS WIRE)– June 11, 2020 ...
FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
Article Link: FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoro...
FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
Article Link: FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoro...
New Small-Cap Report Coming Tuesday June 9th, 2020 at Market Open
Profits, Rapid Growth, Hot Sector, Interested? New report will be available Tuesday 06/09 20 at market open Good day everyone, The markets continue to...
FDA Approves Merck’s Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Article Link: FDA Approves Merck’s Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-...
Late Stage Biotech Citius Pharma (NASDAQ: CTXR) Golden Cross Chart, Recent News and Phase III
Citius Pharma (NASDAQ: CTXR) FDA review data from the phase III trial of MIno-Lok may be a major catalyst for the company shares
Lilly's Taltz (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Article Link: Lilly’s Taltz (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial...
Lilly's Taltz (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Article Link: Lilly’s Taltz (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial...
Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease
Article Link: Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease ...